| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5692208 | Urology | 2016 | 15 Pages |
Abstract
Among nonmetastatic CRPC men, nearly 60% developed metastatic disease during the first 5 years, with most of the metastasis occurring within the first 3 years. Higher Gleason score, receiving primary treatment, higher PSA, and shorter PSA doubling time were independently associated with shorter time to metastasis. Therefore, these variables can be used to stratify patients according to metastasis risk.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Daniel M. Moreira, Lauren E. Howard, Katharine N. Sourbeer, Hiruni S. Amarasekara, Lydia C. Chow, Dillon C. Cockrell, Brian T. Hanyok, William J. Aronson, Christopher J. Kane, Martha K. Terris, Christopher L. Amling, Matthew R. Cooperberg, Alex Liede,